S. Daniel Lynch's most recent trade in SpringWorks Therapeutics Inc was a trade of 232,376 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | Lynch Daniel S. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 232,376 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Lynch S. Daniel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 93,004 | 0 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Lynch Daniel S. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 29,983 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | S. Daniel Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 15,318 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 13,774 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Daniel Lynch S. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 12,216 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Lynch Daniel S. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 7,464 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Lynch Daniel S. | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 6,447 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 14 May 2025 | 10,060 | 93,004 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 20 Feb 2025 | 44,018 | 86,526 (0%) | 0% | 60.1 | 2,647,185 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 20 Feb 2025 | 3,582 | 82,944 (0%) | 0% | 61.2 | 219,349 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 14 Feb 2025 | 400 | 130,544 (0%) | 0% | 60 | 24,000 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 10 Feb 2025 | 69,766 | 236,178 (0%) | 0% | 53.2 | 3,713,553 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 10 Feb 2025 | 65,600 | 130,944 (0%) | 0% | 55.5 | 3,641,751 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 10 Feb 2025 | 39,634 | 196,544 (0%) | 0% | 54.9 | 2,175,047 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 16 May 2024 | 12,216 | 12,216 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 16 May 2024 | 4,095 | 305,944 (0%) | 0% | 0 | Common Stock | ||
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 8,400 | 21,053 | - | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 24 May 2023 | 13,774 | 13,774 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 24 May 2023 | 4,648 | 301,849 (0%) | 0% | 0 | Common Stock | ||
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 14,400 | 14,400 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 7,200 | 12,653 | - | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 19 May 2022 | 15,318 | 15,318 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 19 May 2022 | 4,818 | 297,201 (0%) | 0% | 0 | Common Stock | ||
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 23,342 | 22,981 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 10,500 | 10,337 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 10,500 | 10,337 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 7,660 | 7,660 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 7,000 | 0 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 5,600 | 5,513 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 5,600 | 5,513 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 5,600 | 5,513 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 5,600 | 5,513 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 4,507 | 4,507 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Other type of transaction at price $ 0.00 per share. | 11 Nov 2021 | 4,200 | 4,135 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 3,445 | 3,445 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 3,445 | 3,445 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 2,803 | 5,453 | - | 0 | Common Stock | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 1,837 | 1,837 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 1,837 | 1,837 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 1,837 | 1,837 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 1,837 | 1,837 | - | - | Stock Option (right to buy) | |
| 2seventy bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2021 | 1,378 | 1,378 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | Daniel S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 4,353 | 12,312 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 20 May 2021 | 6,998 | 6,998 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Daniel S. Lynch | Director | 20 May 2021 | 1,106 | 292,383 (0%) | 0% | 0 | Common Stock |